Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
5 hedge funds and large institutions have $890K invested in Avenue Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
72% more capital invested
Capital invested by funds: $517K → $890K (+$373K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$223K |
| 2 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$89.2K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$58K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$29.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $427K | +$223K | +45 | +115% |
|
|
BRWA
2
B. Riley Wealth Advisors
Boca Raton,
Florida
| $281K | +$29.7K | +6 | +12% |
|
|
FWM
3
Frontier Wealth Management
Kansas City,
Missouri
| $90K | +$89.2K | +18 | New |
|
4
BlackRock
New York
| $75K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $17K | -$29.7K | -6 | -67% |
|
|
VF
6
Virtu Financial
New York
| – | -$58K | -14 | Closed |
|
ATXI Hedge Fund Activity: Q1 2018 in Review
5 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2018, worth a combined $890K — up 72% from $517K a quarter earlier.
Fund positioning in ATXI was balanced in Q1 2018: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $223K. The largest seller was Virtu Financial, exiting entirely with an estimated $58K sold.
- 5 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $890K of Avenue Therapeutics, Inc. Common Stock stock for Q1 2018, up 72% quarter-over-quarter.
- 1 fund opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2018 and 1 closed out, a net change of 0 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $223K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2018 was Virtu Financial, an estimated $58K sold.
Based on aggregated 13F filings for Q1 2018.